Background: Iodinated contrast media (CM) are commonly used. Hypersensitivity reactions to CM occasionally result in morbidity. Risk factors and the role of premedication remain to be investigated.
Introduction
Iodinated contrast media (CM) are administered more than 75 million times per year to perform the diagnosis and treatment of several diseases. 1 Hypersensitivity reactions to CM may present immediately as anaphylaxis, which potentially results in fatality. Delayed reactions occur, such as maculopapular exanthema with or without serious reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms).
There are four classes of iodinated CM available including ionic monomers, ionic dimers, non-ionic monomers and non-ionic dimers. Since ionic iodinated CMs are associated with a higher risk of adverse reaction, non-ionic iodinated CMs have been recommended by The American College of Radiology for patients who are at increased risk of adverse reactions. Other risk factors that have been reported are female gender, asthma, β-blocker drugs use, comorbid cardiovascular diseases, 2 and elderly age. 3 Seafood allergy remains to be a concern in general practice as a risk factor for CM reactions. No premedication regimen has consistently been shown to decrease severe adverse events. Therefore, identifying patients who are at increased risk is of clinical significance. The present study was conducted to analyse risk factors, as well as to demonstrate prevalence and clinical outcome of CM reactions.
Methods

Patient selection and study design
This retrospective case-control study was approved by the Institutional Review Board (IRB), allowing access to the medical records of all patients exposed to iodinated CM in Siriraj Hospital, the biggest tertiary hospital in Thailand, from January 1, 2008 -December 31, 2010. CM administrations were performed by doctors (radiologists and residents) and monitored by doctors, nurses or radiology technologists who had received training in CM administration techniques. If a CM reaction occurred, the physician was notified to attend the patient immediately. Finally, the physician was required to complete a CM incident data form. Several CMs used in Siriraj Hospital include ionic CMs (high osmolarity) and non-ionic CMs (iso or low osmolarity).
All incident data forms were reviewed and details including gender, age, information concerning CM usage (indication for CM, type of CM, timing of CM administration/reaction /reaction resolved, premedication used, characteristics of CM reactions), and subsequent patient management were obtained. Using the hospital database, the patient medical records generated on the day of the CM reaction were reviewed for any potential risks of CM reaction and any adverse sequelae.
CM reactions have been classified into 1) toxic, 2) unrelated and 3) hypersensitivity reactions according to Brockow et al. 4 The hypersensitivity reaction is defined as an immediate reaction (onset within 1 hour after CM administration) and nonimmediate or delayed reaction (onset beyond 1 hour after CM administration). Immediate hypersensitivity reactions were classified by the magnitude of severity into 4 grades 5 including grade I: generalised cutaneous and/or mucocutaneous symptoms, grade II: mild systemic reactions, grade III: life threatening systemic reactions, and grade IV: cardiac and/or respiratory arrest. Non-immediate or delayed hypersensitivity reactions were graded as 
Statistical methods
In the first part of the study, 55,286 subjects who were exposed to iodinated CM were enrolled to determine the prevalence of CM adverse reactions. In the second part of the study, the case-control statistical method was applied to determine the risk factors of adverse reaction to CM. All of the 579 subjects who had CM reactions were categorised in the case group. A cohort of 1,175 out of the 55,286 subjects who had no CM reaction was randomised for the control group by using the simple random sampling technique. We used SPSS version 15.0 as a statistical analysis tool. The demographic data and baseline variables were presented using descriptive statistics. The risk factors of CM reaction were analysed by using Chi-square test or Fisher's exact test for categorical variables and using independent T-test or Mann-Whitney U test for continuous variables. Finally, Multiple Logistic Regression was employed for multivariate analysis. Results CM was administered 55,286 times during a 3-year period for patient diagnosis and treatment, of which 579 administrations were reported to result in CM adverse reactions. The overall prevalence was 1.05% (95% CI 0.96-1.14), of which 555 reactions (95.9%) and 24 reactions (4.1%) occurred in adult and paediatric (aged <18) patients, respectively. Individuals with reactions were aged from 4-90 years old (mean 51.5±16.5). The female to male ratio was 1.4:1. Of the 579 CM adverse reactions, 569 (98.3%) and 10 (1.7%) followed administration via intravenous and intra-arterial routes, respectively. Low osmolarity CM (non-ionic iodinated monomer), high osmolarity CM (ionic iodinated monomer and dimer), and iso-osmolarity CM (non-ionic iodinated dimer) were the culprit CMs in 567 (97.9%), 8 (1.4%), and 4 (0.7%) cases, respectively. Among the 67 patients who had repeated reactions, 24 did not receive the premedication, but none developed a serious reaction (Table 1) . Among the patients who had CM reactions, 75.8% (439/579) had at least one comorbid disease, either a non-allergic or allergic comorbid disease, as shown in Table 2 . Clinical manifestations of CM adverse reactions are summarised in Table 3 . Skin involvement was the most frequent manifestation found in 75% of immediate reactions and 100% of non-immediate reactions. Besides cutaneous reactions, the 561 immediate CM reactors exhibited gastrointestinal ) and the respiratory system (chest tightness/ dyspnoea: 5.6%.) There were differences between patients with CM reactions (N=579) and patients who tolerated CM (N=1,175) in terms of gender, history of previous CM reaction and comorbid allergic diseases such as seafood allergy, chronic urticaria, asthma and drug allergy. In a multivariate analysis, as shown in Table 4a , a history of previous CM reaction, female gender and a history of seafood allergy were significant risk factors associated with CM reactions. Female gender, history of seafood allergy and asthma were significantly associated with the first episode of CM reactions. Subgroup analysis revealed that only the history of seafood allergy was a significant risk factor of repeated reactions (N =67) compared to patients who developed a CM reaction in the first episode of exposure (N =512) with an OR of 3.2 (1.5-6.6), p =0.004. In a multivariate analysis, as shown in Table 4b , the most significant risk factor associated with serious CM reactions was asthma, when compared to mild reactions (p =0.013) and controls (p =0.003). Comorbid cardiovascular disease, male gender, history of seafood allergy and a history of previous reaction were significantly associated with mild CM reactions.
Regarding the management of CM adverse reactions, 331 patients (57.1%) were treated as outpatients, 7 patients (1.2%) were hospitalised and one patient (0.2%) died. No medication was given in 240 (41.5%) patients. Medications used for the treatment of CM reactions are summarised in Table  5 .
The various CM reactions were classified as serious reactions if they were grade III or grade IV immediate reactions or severe non-immediate reactions. We found 16 serious reactions in the immediate reaction group. The details of serious CM adverse reactions of each patient were presented according to clinical symptoms and signs, the onset of the reaction, treatment options and outcome, as shown in Table 6 . Seven of sixteen serious reactions were considered to have received inappropriately or potentially harmful management: 4 (patients 2, 5, 7 and 14) received delayed epinephrine injections 10-25 minutes following the onset of the anaphylactic reaction; 2 (patients 10 and 12) did not receive epinephrine, even though anaphylactic reactions were suspected; and 2 (patients 9 and 14) received an improper route of epinephrine administration instead of the intramuscular route. A total of 62 patients developed breakthrough reactions. One of them had a serious reaction within 3 minutes of the administration of a non-ionic iodinated monomer CM via intravenous route. Fortunately, this patient fully recovered after proper treatment and hospitalisation (Patient 2, Table 6 ). In summary, of the patients who suffered from serious reactions, 10 of 16 fully recovered after hospitalisation, 5 of 16 fully recovered after out-patient treatment and one died after the administration of a non-ionic iodinated monomer via intra-arterial route during coronary angiogram (Patient 11, Table 6 ).
Discussion
Our study shows that the overall prevalence of CM adverse reaction was 1.05%. The prevalence of repeated reactions, breakthrough reactions, serious reactions, and fatal reactions were 0.12%, 0.11%, 0.03%, and 0.002%, respectively. Most CM adverse reactions were non-serious immediate reactions, which were significantly associated with a history of previous CM reaction, female gender, and a history of seafood allergy. The first episode of CM reaction was associated with female gender, a history of seafood allergy and asthma. However, only a history of seafood allergy was significantly linked to repeated CM reactions, compared to the first episode of reaction.
The overall prevalence of mild immediate CM reactions has been reported as 3.8% to 12.7% in patients using ionic iodinated CM and 0.7% to 3.1% for non-ionic iodinated CM, 7-9 whereas severe immediate reactions have been reported in 0.1% to 0.4% and 0.02% to 0.04% of patients for ionic iodinated CM and non-ionic iodinated CM, respectively. [7] [8] [9] [10] The frequency of non-immediate CM reactions ranges from 0.5% to 23%, 11 which were mild and self-limited. 2 Unlike immediate CM reactions, there appears to be a higher incidence of non-immediate CM reactions associated with nonionic iodinated dimer CM, but not with other types of CM 12 . Our prevalence rates of immediate reaction (1.01%) and severe immediate reaction grade III and grade IV (0.03%) are comparable with previous reports, whereas the frequency of non-immediate reaction in our study was only 0.03%. This is probably due to the difficulty in verifying whether symptoms that occurred days after CM exposure were, in fact, caused by the CM, and the variations in the clinical manifestations in non-immediate reactions. 13 The main risk factor for both immediate and nonimmediate hypersensitivity reaction is a history of previous CM reaction, which poses a 21% to 60% risk of a repeated reaction. 4, 11, 14, 15 Other risk factors include female gender, asthma, and ß-blocker drug use. 3 were at increased risk of serious or fatal reaction. The most striking risk factor in our study was a history of seafood allergy which was significantly associated with both the first episode of reactions and repeated CM reactions. A systematic review from 7 prospective studies (75,616 CM injections) showed that allergies to shellfish were associated with the same minimal increased risk of reaction to CM injection as other forms of atopy such as asthma and other food allergies. 16 This indicates that a general atopic disposition, rather than an iodine-specific reactivity, accounts for the increased incidence of CM reactions in this sub-group. Thus, reactions to CM should not be considered to be associated with an IgE-mediated iodine allergy, and allergy to shellfish does not change the risk of CM reaction compared to other allergies. 17 Nevertheless, further studies are needed to clarify whether the history of seafood allergy in our patients is truly an allergy; some patients may require skin testing and/or food challenge.
Repeated CM reactions occasionally develop despite premedication so-called breakthrough reactions. [18] [19] [20] [21] [22] Sixty-two breakthrough reactions occurred (0.11%) in our study, of which one serious reaction was noted. Evidence from a systematic review suggests that 100-150 of unselected patients required an oral double dose of methylprednisolone to prevent a one potentially life threatening CM reaction. 22 There is no valid data supporting the efficacy of steroid and/or antihistamine administration in patients with a history of allergic reactions. 22 Other strategies to prevent CM hypersensitivity reactions according to the guidelines of the American College of Radiology include the use of non-ionic iodinated CM in patients who are at increased risk of reaction, such as patients with previous CM reactions, asthma, multiple true allergies or diseases that increase the risk of adverse reactions, e.g. pheochromocytoma, hyperthyroidism, thyroid cancer, renal failure. 23 One patient with coronary artery disease in this study died during a coronary angiogram procedure that used CM via an intra-arterial route; the cause of death, due to either coronary artery disease or CM hypersensitivity, remained inconclusive. Nevertheless, previous studies have reported a significant difference between the intra-arterial and intravenous administration of CMs, with higher rates of reaction associated with an intra-arterial application. [24] [25] [26] Taken together, the prevalence of CM reactions in our study was 1.05%. A previous history of CM reaction and female gender were the main risk factors for CM reactions, whereas asthma was shown to be a significant risk factor for serious reactions. Whether seafood allergy is a risk factor remains to be investigated. More studies are required to reduce the morbidity and mortality of such reactions.
